Interaction index and different methods for determining drug interaction in combination therapy

被引:108
|
作者
Lee, J. J.
Kong, M.
Ayers, G. D.
Lotan, R.
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[2] Univ Louisville, Dept Biostat & Bioinformat, Louisville, KY 40292 USA
[3] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA
[4] Univ Texas, MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA
关键词
antagonism; drug interaction; Loewe additivity model; response surface model; synergy;
D O I
10.1080/10543400701199593
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Studying and understanding the joint effect of combined treatments is important in pharmacology and in the development of combination therapies. The Loewe additivity model is one of the best general reference models for evaluating drug interactions. Based on this model, synergy occurs when the interaction index is less than one, while antagonism occurs when interaction index is greater than one. We expound the meaning of the interaction index, and propose a procedure to calculate the interaction index and its associated confidence interval under the assumption that the dose-effect curve for a single agent follows Chou and Talalay's median effect equation. In addition, we review four response surface models based on the Loewe additivity model using a single parameter to determine drug interactions. We describe each of these models in the context of Loewe additivity model and discuss their relative advantages and disadvantages. We also provide S-PLUS/R code for each approach to facilitate the implementation of these commonly used methods.
引用
收藏
页码:461 / 480
页数:20
相关论文
共 50 条
  • [1] Estimating the Interaction Index in Drug Combination Experiments
    Fan, Chunpeng
    Zhang, Donghui
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2014, 6 (02): : 144 - 153
  • [2] Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction
    Lee, J. Jack
    Kong, Maiying
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2009, 1 (01): : 4 - 17
  • [3] The interaction index: a measure of drug synergism
    Tallarida, RJ
    PAIN, 2002, 98 (1-2) : 163 - 168
  • [4] DRUG INTERACTION IN DIGITALIS THERAPY
    CARBONIN, PU
    COCCHI, A
    MINERVA CARDIOANGIOLOGICA, 1977, 25 (11): : 881 - 888
  • [5] DNA Interaction Studies of an Antiviral Drug, Ribavirin, Using Different Instrumental Methods
    Shahabadi, Nahid
    Kalar, Zeinab Mirzaei
    Rayegani, Asad Veysi
    DNA AND CELL BIOLOGY, 2012, 31 (05) : 876 - 882
  • [6] Determining calmodulin binding to metabotropic glutamate receptors interaction methods with distinct protein-interaction methods
    Lidwell, K
    Dillon, J
    Sihota, A
    O'Connor, V
    Pilkington, B
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2004, 32 : 868 - 870
  • [7] COMBINATION THERAPY DESIGN FOR TARGETED THERAPEUTICS FROM A DRUG-PROTEIN INTERACTION PERSPECTIVE
    Haider, Saad
    Berlow, Noah
    Pal, Ranadip
    Davis, Lara
    Keller, Charles
    2012 IEEE INTERNATIONAL WORKSHOP ON GENOMIC SIGNAL PROCESSING AND STATISTICS (GENSIPS), 2012, : 58 - 61
  • [8] Intolerance of dolutegravir-containing combination antiretroviral therapy: not just a pharmacokinetic drug interaction
    Cattaneo, Dario
    Rizzardini, Giuliano
    Gervasoni, Cristina
    AIDS, 2017, 31 (06) : 867 - 868
  • [9] Impact of Drug-Gene-Interaction, Drug-Drug-Interaction, and Drug-Drug-Gene-Interaction on (es)Citalopram Therapy: The PharmLines Initiative
    Bahar, Muh. Akbar
    Lanting, Pauline
    Bos, Jens H. J.
    Sijmons, Rolf H.
    Hak, Eelko
    Wilffert, Bob
    JOURNAL OF PERSONALIZED MEDICINE, 2020, 10 (04): : 1 - 20
  • [10] DRUG INTERACTION DURING ANTICONVULSIVE THERAPY
    WINDORFER, P
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND BIOPHARMACY, 1976, 14 (03): : 236 - 236